http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
허창원,장지혜,김려연,허성근,김태우,하판봉,김영희,Heo, Chang-Won,Jang, Ji-Hye,Jin, Liyan,Heo, Sung-Kyn,Kim, Tae-Woo,Ha, Pan-Bong,Kim, Young-Hee 한국정보통신학회 2013 한국정보통신학회논문지 Vol.17 No.10
본 논문에서는 의료영상 뿐만 아니라 비파괴검사 등에 활용되고 있는 CMOS x-ray 라인 스캔 센서를 설계하였다. x-ray 라인 스캔 센서는 512열${\times}$4행의 픽셀 어레이(pixel array)를 갖고 있으며, DC-DC 변환기(converter)를 내장하였다. Binning 모드를 이용하여 픽셀 사이즈가 $100{\mu}m$, $200{\mu}m$, $400{\mu}m$이 되도록 선택할 수 있도록 하기 위해 no binning 모드, $2{\times}2$ binning 모드와 $4{\times}4$ binning 모드를 지원하는 픽셀 회로를 새롭게 제안하였다. 그리고 power supply noise와 입력 common mode noise에 둔감한 이미지 신호인 fully differential 신호를 출력하도록 설계하였다. $0.18{\mu}m$ x-ray CMOS 이미지 센서 공정을 이용하여 설계된 라인 스캔 센서의 레이아웃 면적은 $51,304{\mu}m{\times}5,945{\mu}m$ 이다. A CMOS x-ray line scan sensor which is used in both medical imaging and non-destructive diagnosis is designed. It has a pixel array of 512 columns ${\times}$ 4 rows and a built-in DC-DC converter. The pixel circuit is newly proposed to have three binning modes such as no binning, $2{\times}2$ binning, and $4{\times}4$ binning in order to select one of pixel sizes of $100{\mu}m$, $200{\mu}m$, and $400{\mu}m$. It is designed to output a fully differential image signal which is insensitive to power supply and input common mode noises. The layout size of the designed line scan sensor with a $0.18{\mu}m$ x-ray CMOS image sensor process is $51,304{\mu}m{\times}5,945{\mu}m$.
허주선,김규리,김윤주,신승한,이재명,이주영,손진아,이진아,최창원,김이경,김한석,김병일,최중환 대한신생아학회 2012 Neonatal medicine Vol.19 No.1
Purpose: This study was aimed to evaluate the neonatal mortality and morbidity of infants affected by twin-twin transfusion syndrome (TTTS) compared to the control twins matched for gestational age. Also the perinatal outcomes of donor parts of TTTS twins with their counterpart recipients were compared. Methods: A retrospective case-control study was conducted from infants born at Seoul National University Children’s Hospital and Seoul National University Bundang Hospital between April 2005 and July 2011. Eighteen pairs of TTTS infants were allocated to the TTTS group. The control group consisted of 36 pairs of twin infants unaffected by TTTS who were matched for gestational age. Neonatal deaths and morbidities were recorded. Results: The mortality in TTTS group was significantly higher than control group (27.8% vs. 4.2%, P=0.001). The incidence of acute renal failure (41.2% vs. 9.7%, P<0.001), cardiac ventricular hypertrophy (31.3% vs. 2.9%, P<0.001), congestive heart failure (45.7%vs. 5.6%, P<0.001), grade ≥2 intraventricular hemorrhage (33.3% vs. 11.1%, P=0.012) and grade ≥2 periventricular leukomalacia (24.2% vs. 2.8%, P=0.001) were significantly higher in TTTS group than control group. There was no significant difference in mortality and morbidities between donors and recipients except significantly higher incidence of acute renal failure in donors (70.6%vs. 11.8%, P=0.001). Conclusion: Twin infants affected by TTTS have higher risk of neonatal death and several severe morbidities. These results indicate that alert monitoring and checking about possible morbidities are very important in newborns with TTTS and early intervention is critical for improving the overall outcome of the affected infants. 목적: 분만 후 생존한 쌍생아간 수혈 증후군 환자군과 주수를 짝지은 대조군을 비교함으로써 쌍생아 수혈 증후군의 신생아기 사망률 및 이환율을 분석하고 쌍생아간 수혈 증후군 내의 공혈자와 수혈자 간에도 사망률과 이환률을 비교하여 이를 토대로 쌍생아 수혈 증후군 환자의 진료에 도움이 되고자 한다. 방법: 2005년 4월부터 2011년 7월까지 서울대병원 어린이병원과분당 서울대병원에 입원한 환아를 대상으로 환자-대조군 연구를 시행하였다. 총 18쌍의 쌍생아간 수혈 증후군 환자와 36쌍의 주수를짝지은 쌍생아 대조군을 대상으로 후향적으로 신생아기 사망, 합병증에 대해 의무 기록을 고찰하였다. 결과: 쌍생아 간 출생 체중, 혈색소 차이는 쌍생아간 수혈 증후군에서 대조군에 비해 유의하게 높았다(29.9% vs. 10.1%, P<0.001; 0.2g/dL vs. -0.3 g/dL, P=0.024). 신생아기 사망률은 쌍생아간 수혈 증후군에서 유의하게 높았다(27.8% vs. 4.2%; P=0.001). 두 군간 신생아기 이환율을 비교하였을 때 쌍생아간 수혈 증후군에서 유의하게 높게 나타난 것은 급성 신부전(41.2% vs. 9.7%, P<0.001), 중등도 이상의 삼첨판 역류(12.5% vs. 1.4%, P=0.033), 심실 비대 (31.3% vs. 2.9%, P<0.001), 울혈성 심부전(45.6% vs. 5.6%, P<0.001), 2단계 이상의뇌실내 출혈(45.7% vs. 5.6%, P<0.001), 2단계 이상의 뇌실주위 백질연화증(24.2% vs. 2.8%, P=0.001)이었다. 쌍생아간 수혈 증후군 내의공혈자와 수혈자 간에 신생아기 사망률에는 유의한 차이가 없었으며, 두 군 간에 통계학적으로 유의한 차이가 있었던 합병증은 급성신부전(70.6% vs. 11.8%; P=0.001)이었고 그 외 심부전, 뇌실내 출혈,뇌실주위 백질 연화증을 포함한 다른 합병증에는 차이가 없었다. 결론: 쌍생아간 수혈 증후군 환아는 그렇지 않은 쌍생아에 비해신생아기 사망률 및 몇 가지 중대한 신생아기 질병 이환율이 유의하게 높았다. 따라서 출생 후 환아의 혈역학적 변화 및 발병 가능한 합병증에 대해 집중적으로 감시, 관찰하는 것이 매우 중요하며 발병시조기에 치료하는 것이 환아의 전체적인 예후에 큰 영향을 미칠 것이다.
허주선,Ka Young Choi,Se Hyoung Sohn,Curie Kim,Yoon Joo Kim,Seung Han Shin,Jae Myung Lee,이주영,Jin A Sohn,Byung Chan Lim,이진아,최창원,Ee Kyung Kim,Han Suk Kim,Beyong Il Kim,최중환 대한소아청소년과학회 2012 Clinical and Experimental Pediatrics (CEP) Vol.55 No.11
Mucolipidosis II (ML II) or inclusion cell disease (I-cell disease) is a rarely occurring autosomal recessive lysosomal enzyme-targeting disease. This disease is usually found to occur in individuals aged between 6and 12 months, with a clinical phenotype resembling that of Hurler syndrome and radiological findings resembling those of dysostosis multiplex. However, we encountered a rare case of an infant with ML II who presented with prenatal skeletal dysplasia and typical clinical features of severe secondary hyperparathyroidism at birth. A female infant was born at 37+1 weeks of gestation with a birth weight of 1,690 g (<3rd percentile). Prenatal ultrasonographic findings revealed intrauterine growth retardation and skeletal dysplasia. At birth, the patient had characteristic features of ML II, and skeletal radiographs revealed dysostosis multiplex, similar to rickets. In addition, the patient had high levels of alkaline phosphatase and parathyroid hormone,consistent with severe secondary neonatal hyperparathyroidism. The activities of β-D-hexosaminidase and α-N-acetylglucosaminidase were moderately decreased in the leukocytes but were 5- to 10-fold higher in the plasma. Examination of a placental biopsy specimen showed foamy vacuolar changes in trophoblasts and syncytiotrophoblasts. The diagnosis of ML II was confirmed via GNPTAB genetic testing, which revealed compound heterozygosity of c.3091C>T (p.Arg1031X) and c.3456_3459dupCAAC (p.Ile1154GlnfsX3), the latter being a novel mutation. The infant was treated with vitamin D supplements but expired because of asphyxia at the age of 2 months.